192 related articles for article (PubMed ID: 29150104)
1. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.
Jaime-Pérez JC; Gamboa-Alonso CM; Padilla-Medina JR; Jiménez-Castillo RA; Olguín-Ramírez LA; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D
Rev Bras Hematol Hemoter; 2017; 39(4):325-330. PubMed ID: 29150104
[TBL] [Abstract][Full Text] [Related]
2. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma.
Cortez AJ; Dulley FL; Saboya R; Mendrone Júnior A; Amigo Filho U; Coracin FL; Buccheri V; Linardi Cda C; Ruiz MA; Chamone Dde A
Rev Bras Hematol Hemoter; 2011; 33(1):10-4. PubMed ID: 23284236
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
Zhu YJ; Sun YL; Xia Y; Jiang WQ; Huang JJ; Huang HQ; Lin TY; Guan ZZ; Li ZM
Med Oncol; 2012 Jun; 29(2):1127-33. PubMed ID: 21390515
[TBL] [Abstract][Full Text] [Related]
9. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
[TBL] [Abstract][Full Text] [Related]
10. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
[TBL] [Abstract][Full Text] [Related]
11. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
15. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
16. Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's Lymphoma.
Tan GF; Goh S; Chang EWY; Tan YH; Chiang J; Yang VS; Poon EYL; Somasundaram N; Bin Harunal Rashid MF; Tao M; Lim ST; Ong CK; Chan JY
Hematol Rep; 2023 Feb; 15(1):108-118. PubMed ID: 36810555
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid.
Rubio R
Cancer; 1994 May; 73(9):2400-7. PubMed ID: 8168044
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
[TBL] [Abstract][Full Text] [Related]
19. [Treatment results of Hodgkin's lymphoma].
Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
